Sangamo Therapeutics, Inc. Overview
Pro stress-test →Sangamo Therapeutics is a clinical-stage genomic medicine company that focuses on translating science into medicines transforming the lives of patients with serious diseases. The company uses proprietary zinc finger technology to create genomic cures for diseases where current medicine offers only symptom management.
Strategic Profile
Pro stress-test →Key clinical assets include ST-920 (Phase 1/2 for Fabry disease), TX200 (Phase 1/2 for kidney transplant rejection), and SB-525 (Phase 3 for hemophilia A). The company maintains significant strategic partnerships with Biogen, Pfizer, Sanofi, Novartis, and Kite Pharma, with preclinical programs targeting neurological diseases including ALS/FTD and Huntington's.
Competitive Landscape
Pro stress-test →Among 75 identified competitors, Intellia Therapeutics represents a similar-stage genomic medicine company. The competitive landscape includes other gene therapy and cell therapy developers like Editas Medicine and uniQure. Sangamo differentiates through its zinc finger and epigenetic regulation technologies, though it faces intense competition from better-capitalized peers and larger pharma partners developing similar therapies.
Industry Context
Sangamo Therapeutics, Inc. operates in Biotechnology / Genomic Medicine.
Key facts
Founded: 1995 · Headquarters: Richmond, US · Employees: 183 · Revenue: $57.8M (2024) · Market cap: $138.2M